CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.420
-0.030 (-0.67%)
Apr 24, 2026, 1:21 PM EDT - Market open
CytomX Therapeutics Revenue
In the year 2025, CytomX Therapeutics had annual revenue of $76.20M, down -44.82%. CytomX Therapeutics had revenue of $663.00K in the quarter ending December 31, 2025, a decrease of -98.26%.
Revenue (ttm)
$76.20M
Revenue Growth
-44.82%
P/S Ratio
12.56
Revenue / Employee
$1,104,362
Employees
69
Market Cap
962.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 76.20M | -61.90M | -44.82% |
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
| Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
| Dec 31, 2017 | 71.62M | 58.78M | 457.59% |
| Dec 31, 2016 | 12.85M | 6.90M | 116.21% |
| Dec 31, 2015 | 5.94M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 888.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xeris Biopharma Holdings | 291.85M |
| Geron | 183.88M |
| Phathom Pharmaceuticals | 175.11M |
| Xencor | 125.58M |
| KalVista Pharmaceuticals | 73.62M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
| Compass Therapeutics | 850.00K |
CTMX News
- 5 weeks ago - Why Is CytomX Therapeutics Stock Falling On Wednesday? - Benzinga
- 5 weeks ago - CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally - Benzinga
- 5 weeks ago - CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer - GlobeNewsWire
- 5 weeks ago - CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
- 7 weeks ago - CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 - GlobeNewsWire